• Bradford Protein Assay Kit: Practical Protocol

  2026-09-18

  The Bradford Protein Assay Kit (SKU K4103) provides rapid protein concentration measurement from small-volume solution samples using Coomassie dye and absorbance at 595 nm. It is suited to routine enzyme, purification, and molecular biology workflows, but should not be treated as a protein purity test or used without compatibility checks for detergent-containing buffers.

• Mtb–BMX Signaling Blocks Lysosomal Acidification

  2026-09-18

  The reference study identifies a host–pathogen mechanism in which Mycobacterium tuberculosis secretes Chp2/Rv1184 to promote BMX-dependent phosphorylation of ATP6V1E1, disrupting V-ATPase assembly and lysosomal acidification. The findings connect a specific host kinase to intracellular Mtb survival and provide a rationale for evaluating BMX inhibition in host-directed tuberculosis models.

• Epalrestat Workflows for Oxidative Stress Research

  2026-09-17

  Epalrestat combines aldose reductase inhibition with a mechanism-linked KEAP1/Nrf2 research hypothesis, making it useful for connecting polyol pathway biology, oxidative stress, and neuronal injury. This practical guide covers solvent handling, cell and animal model design, orthogonal validation, and troubleshooting for diabetic neuropathy research and Parkinson’s disease model workflows.

• Anlotinib Hydrochloride: From Assay to Evidence

  2026-09-17

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that connects receptor-level signaling, endothelial phenotypes, and translational cancer research. This guide explains how to interpret its anti-angiogenic activity without confusing pathway inhibition with clinical proof.

• Propidium Iodide Workflows for Cell Death Studies

  2026-09-16

  Build more informative viability, apoptosis, and cell cycle assays with Propidium iodide, from routine flow cytometry to host–pathogen models. This guide translates the GRA12 virulence study into practical membrane-integrity readouts while emphasizing controls, gating, and interpretation limits.

• SERT–nNOS Blockade and Fast-Onset Antidepressant Action

  2026-09-16

  The reference study identifies disruption of the serotonin transporter–neuronal nitric oxide synthase (SERT–nNOS) complex as a strategy for accelerating antidepressant responses. Using mBRET screening, stress-based mouse models, behavioral testing, and rs-fMRI, the authors show that esflurbiprofen modifies dorsal raphe nucleus circuitry and produces rapid antidepressant-like effects.

• Epalrestat Workflows for Polyol Pathway Research

  2026-09-15

  Build reproducible aldose reductase inhibition studies across diabetic neuropathy research, oxidative stress research, and emerging cancer-metabolism models. This guide connects Epalrestat preparation, pathway-focused controls, quantitative readouts, and troubleshooting to the fructose-metabolism framework described in recent cancer research.

• CCCP for Mitochondrial Morphology Assays

  2026-09-15

  CCCP converts mitochondrial imaging from a static snapshot into a controlled stress-response experiment by imposing mitochondrial proton gradient disruption. This article explains how to use carbonyl cyanide m-chlorophenyl hydrazine alongside live-cell imaging and deep-learning analysis while separating assay validation from claims about Alzheimer’s disease.

• Predictive siRNA Codelivery with Netarsudil

  2026-09-14

  Slaughter et al. developed a quantitative framework that links ionizable-drug structure to siRNA complexation and nanoparticle encapsulation. The study identified Netarsudil as a high-performing candidate and demonstrated CTGF siRNA codelivery with reduced CTGF expression and actin-network density in fibrotic human trabecular meshwork cells.

• Trichostatin A (TSA): Mechanism and Research Use

  2026-09-14

  Trichostatin A (TSA) is a reversible histone deacetylase inhibitor used to study chromatin acetylation, differentiation, and cancer biology. Its research value comes from reproducible histone hyperacetylation and context-dependent effects on proliferation, cell-cycle progression, and combination treatment responses.

• BX795: From Kinase Potency to Translational Signal

  2026-09-13

  BX795 is more than a potent PDK1 inhibitor: its simultaneous activity toward PDK1, TBK1, and IKKε creates an opportunity to connect kinase engagement with cancer phenotypes and innate immune signaling. This article outlines a translational workflow that separates pathway inhibition, cytostasis, and cell death while defining where BX795 is informative—and where its polypharmacology requires caution.

• ATG4B Nuclear Translocation Drives AML Instability

  2026-09-12

  A 2025 Advanced Science study identifies energy deficiency-induced nuclear translocation of ATG4B as a direct inhibitor of PRMT1-dependent DNA repair in acute myeloid leukemia. The work links metabolic stress to MRE11 methylation, genomic instability, leukemia progression, and therapeutic vulnerability through complementary cellular, mouse, and patient-derived models.

• Silybin A: Reproducible Silymarin Workflows

  2026-09-11

  Build solvent-aware, stereochemically defined assays for oxidative stress reduction, inflammatory signaling, and liver injury models with Silybin A rather than an incompletely characterized botanical mixture. This practical guide covers stock preparation, dosing, analytical controls, and troubleshooting for hepatoprotective and metabolic studies.

• Annexin V-FITC/PI Apoptosis Assay Kit Workflow

  2026-09-11

  Turn phosphatidylserine externalization and membrane integrity into a practical, single-cell readout for renal cancer drug studies. This workflow shows how to use the Annexin V-FITC/PI Apoptosis Assay Kit to separate viable, early apoptotic, late apoptotic, and necrotic populations while avoiding common interpretation and staining errors.

• FAISL–FAK Proteolysis in Triple-Negative Breast Cancer

  2026-09-10

  The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by blocking Calpain 2-mediated proteolysis, thereby promoting triple-negative breast cancer progression and metastasis. Its combination of transcriptomic analysis, RNA–protein interaction mapping, functional assays, and nanoparticle-mediated FAISL silencing defines a mechanistic and potentially actionable regulatory axis.

7650 records 1/510 page Next 12345 下5页 Last page